27588 Federal Register / Vol. 63, No. 96 /Tuesday, May 19, 1998 / Notices

Inc., 3858 Benner Road, Miamisburg,

Ohio 45342, made application by

renewal to the Drug Enforcement

Administration (DEA) to be registered as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

Cathinone (1235) ........................ I

Methacathinone (1237) ............... I

N-Ethylamphetamine (1475) ....... I

N,N-Dimethylamphetamine

(1480).

I

Aminorex (1585) ......................... I

Methaqualone (2565) .................. I

Lysergic acid diethylamide

(7315).

I

Tetrahydrocannabinols (7370) .... I

Mescaline (7381) ........................ I

2, 5-Dimethoxyamphetamine

(7396).

I

3,4-Methylenedioxyamphetamine

(7400).

I

3, 4-Methylenedioxy-Nethylamphetamine (7404).I

3,4-Methylenedioxymeth- amphetamine (7405).I

4-Methoxyamphetamine (7411) .. I

Psilocybin (7437) ........................ I

Psilocyn (7438) ........................... I

N-Ethyl-1-phenylcyclohexylamine

(7455).

I

Dihydromorphine (9145) ............. I

Normorphine (9313) .................... I

Acetylmethadol (9601) ................ I

Alphacetylmethadol Except

Levo-Alphacetylmethadol

(9603).

I

Normethadone (9635) ................. I

3-Methylfentanyl (9813) .............. I

Amphetamine (110e) .................. II

Methamphetamine (1105) ........... II

Methylphenidate (1724) .............. II

Amobarbital (2125) ..................... II

Pentobarbital (2270) ................... II

Secobarbital (2315) .................... II

1-Phenylcyclohexylamine (7460) II

Phencyclidine (7471) .................. II

Phenylacetone (8501) ................. II

1-Piperidinocyclohexanecarbonitrile (8603).II

Codeine (9050) ........................... II

Dihydrocodeine (9120) ............... II

Oxycodone (9143) ...................... II

Hydromorphone (9150) ............... II

Benzoylecgonine (9180) ............. II

Ethylmorphine (9190) ................. II

Hydrocodone (9193) ................... II

Isomethadone (9226) .................. II

Meperidine (9230) ....................... II

Methadone (9250) ...................... II

Methadone intermediate (9254) II

Dextropropoxyphene, bulk nondosage forms) (9273).II

Morphine (9300) ......................... II

Levo-Alphacetylmethadol (9648) II

Oxymorphone (9652) .................. II

Fentanyl (9801) ........................... II

The firm plans to use small quantities

of the listed controlled substances to

produce standards for analytical

laboratories.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Isotec, Inc. to

manufacture the listed controlled

substances is consistent with the public

interest at this time. Therefore, pursuant

to 21 U.S.C. 823 and 28 CFR §§ 0.100

and 0.104, the Deputy Assistant

Administrator, Office of Diversion

Control, hereby orders that the

application submitted by the above firm

for registration as a bulk manufacturer

of the basic classes of controlled

substances listed above is granted.

Dated: May 6, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13322 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on February 4,

1998, Lonza Riverside, 900 River Road,

Conshohocken, Pennsylvania 19428,

made application by renewal to the

Drug Enforcement Administration

(DEA) for registration as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Amphetamine (1100) .................... II

Phenylacetone (8501) ................... II

The firm plans to manufacture the

listed controlled substances in bulk for

distribution to its customers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 20,

1998.

Dated: May 7, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–13328 Filed 5–18–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1301.34 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on February 4, 1998, Lonza

Riverside, 900 River Road,

Conshohocken, Pennsylvania 19428,

made application by renewal to the

Drug Enforcement Administration to be

registered as an importer of

phenylacetone (8501), a basic class of

controlled substance listed in Schedule

II.

The firm is importing the

phenylacetone to manufacture

dextroamphetamine sulfate.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than June 18, 1998.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46